GLP-1
Adocia announced that the American Arbitration Association Tribunal governing Adocia’s arbitration claims against Eli Lilly & Company dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly.
Emery Pharma and CP Lab Safety will be attending the American Chemical Society’s National Meeting & Expo in San Diego, California on August 25 – 27, 2019.
Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
D&D Pharmatech is the parent company of U.S.-based Neuraly, Precision Molecular and Theraly Fibrosis. All three are spinouts from Johns Hopkins School of Medicine.
LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
Novo Nordisk intends to use the site to support manufacturing of its oral type 2 diabetes treatment that is under review for approval by the U.S. Food and Drug Administration.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
PRESS RELEASES